18 results
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
Influenza A and B virus ... Varicella-zoster virus ... • Hepatitis A virus ... • Hepatitis B virus ... #IDSA #management
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
Influenza A and B virus ... Varicella-zoster virus ... • Hepatitis A virus ... • Hepatitis B virus ... #IDSA #management
MonkeyPox Virus - Summary Review - What we know so far

 • History
 • Epidemiology
 •
MonkeyPox Virus ... Diagnosis • Treatment ... Monkeypox #diagnosis #management ... #virus #infectiousdiseases ... #microbiology #treatment
Here is a quick guide on the common direct-acting antivirals (DAAs) for chronic hepatitis C virus
chronic hepatitis C virus ... Antivirals #table #treatment ... #medications #infectiousdisease ... HepC #HepatitisC #Management
Ivermectin. Old anti-parasitic agent making a comeback with recent headlines from in-vitro study that showed antiviral
SARS-CoV-2, the virus ... Pandemic #Outbreak #InfectiousDiseases ... #Pharmacology #Treatment ... #Virus #Antiviral ... #Management #Ivermectin
Infectious Causes of Adrenal Insufficiency
Anatomical distribution of vessels to the adrenal makes the gland prone to
Waterhouse-Friderichsen syndrome ... canimorsus • Virus ... Cytomegalovirus, Epstein-Barr ... virus, Herpes simplex ... virus, Echovirus
Guillain-Barre Syndrome - Summary

Acute AIDP that presents with rapidly progressive flaccid weakness

Epidemiology:
 • 1-2 cases/100,000 per
Guillain-Barre Syndrome ... COVID 19 - Zika virus ... Treatment: • Plasmapheresis ... #Syndrome #diagnosis ... #management #treatment
Guillain-Barré Syndrome (GBS)
Acute autoimmune demyelinating polyradiculoneuropathy that presents with rapidly progressive flaccid weakness
Epidemiology:
 • Incidence: 1
Guillain-Barré Syndrome ... virus, human immunodeficiency ... virus (HIV), and ... Zika virus • Other ... #management #neurology
IDSA Treatment Recommendations for Cryptococcal Meningoencephalitis in Human Immunodeficiency Virus Infected Individuals
Induction therapy:
 • AmBd (0.7–1.0
IDSA Treatment Recommendations ... Immunodeficiency Virus ... Meningoencephalitis #IDSA ... #Treatment #management ... #cryptococcus #HIVAIDS
IDSA Treatment Recommendations for Cryptococcal Meningoencephalitis - Induction, Consolidation and Maintenance Therapy

Table 2. Antifungal Treatment Recommendations
IDSA Treatment Recommendations ... Immunodeficiency Virus–Infected ... Immunodeficiency Virus ... Meningoencephalitis #IDSA ... #Treatment #management